Recombinant Bacille Calmette–Guérin for Immunotherapy in Nonmuscle Invasive Bladder Cancer
Korean Journal of Urological Oncology
;
: 109-117, 2016.
Artículo
en Coreano
| WPRIM
| ID: wpr-215747
ABSTRACT
Intravesical instillation of Mycobacterium bovis bacille Calmette–Guérin (BCG) has been used for treating nonmuscle invasive bladder cancer as the forefront of immunotherapy, but BCG is ineffective in approximately 30–40% of cases and disease recurs in up to 50% of patients. Recently BCG is considered an effective vehicle for delivery of antigens due to its unique characteristics, and the genetic control of these mycobacteria is advanced in the search for less toxic and more potent therapeutic agents for bladder cancer immunotherapy. We will discuss current advances in recombinant BCG construction, research, and future directions.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Vejiga Urinaria
/
Neoplasias de la Vejiga Urinaria
/
Administración Intravesical
/
Vacuna BCG
/
Inmunoterapia
/
Mycobacterium bovis
Límite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Urological Oncology
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS